Spondyloarthritis & psoriatic arthritis
Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the European Spondyloarthritis (EuroSpA) Collaboration
Authors' conclusion
We identified overall and sex-specific predictors of SEC effectiveness in European patients with PsA.
Study context
- Population
- Patients with psoriatic arthritis (PsA) aged ≥ 18 years at diagnosis initiating secukinumab (SEC) in routine care, January 2015 to January 2021, 14 European registries43% male
- Participants
- 2,790 patients
- Outcome
- Baseline predictors of (1) DAPSA28 LDA (DAPSA28 ≤ 14) at 6 months, (2) DAPSA28 moderate response at 6 months, (3) SEC discontinuation within 12 months
Methodological detailsregistry-based, 14 registries in the EuroSpA Research Collaboration, multiple imputation, logistic and Cox regressions, overall and sex-stratified analyses
- Registry-based
- 14 registries in the EuroSpA Research Collaboration
- Multiple imputation
- Logistic and Cox regressions
- Overall and sex-stratified analyses
Main finding
As reported in the abstract
Baseline predictors of SEC effectiveness
- Positive predictors of both DAPSA28 low disease activity (LDA) and DAPSA28 moderate response: male sex, fewer previous b/tsDMARDs, C-reactive protein (CRP) > 10 mg/L, lower Health Assessment Questionnaire (HAQ) score
- Predictors of SEC discontinuation within 12 months: absence of psoriasis, higher patient fatigue, tender joint counts
- Sex-specific predictors for some outcomes: fewer previous b/tsDMARDs and CRP > 10 mg/L in males; lower patient fatigue score in females
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Median age, years (IQR 34-52)
- 43
- SEC as first-line b/tsDMARD, patients (24%)
- 665
Original publication
Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration. J Rheumatol. Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →